It is likely that DHS and other PH inhibitors will never have clinical applications on account of their capacity for inducing hyperphenylalaninemia and phenylketonuria.
DHS i drugi PH inhibitori verovatno neće ući u kliničku upotrebu zbog njihove sposobnosti da indukuju hiperfenilalaninemiju i fenilketonuriju.